Literature DB >> 16406098

Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.

Irina Gurt1, Ihab Abdalrhman, Ehud Katz.   

Abstract

The pathogenicity and immunogenicity in mice of WR.cl and WR.c3, two mutants of the Western Reserve (WR) strain of vaccinia virus, mutated in the A33R and B5R proteins of the outer envelope of the virus, respectively, were studied. WR.c1 was the most attenuated virus, WR.c3 was somewhat more pathogenic, while WR was the most virulent of the three. While the WR and the WR.c3 viruses, intranasally inoculated into mice, spread efficiently to the different internal organs of the animal, including the brain, WR.c1 was restricted to the lungs only. Mice, intranasally infected with 500 plaque forming units of the WR, WR.c1, or WR.c3 viruses, were protected against infection with a lethal dose of the WR strain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16406098     DOI: 10.1016/j.antiviral.2005.11.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  The structure of the poxvirus A33 protein reveals a dimer of unique C-type lectin-like domains.

Authors:  Hua-Poo Su; Kavita Singh; Apostolos G Gittis; David N Garboczi
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

3.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

4.  Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice.

Authors:  Marina Zaitseva; Senta M Kapnick; John Scott; Lisa R King; Jody Manischewitz; Lev Sirota; Shantha Kodihalli; Hana Golding
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

5.  Oral Tecovirimat for the Treatment of Smallpox.

Authors:  Douglas W Grosenbach; Kady Honeychurch; Eric A Rose; Jarasvech Chinsangaram; Annie Frimm; Biswajit Maiti; Candace Lovejoy; Ingrid Meara; Paul Long; Dennis E Hruby
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 176.079

6.  Loss of Actin-Based Motility Impairs Ectromelia Virus Release In Vitro but Is Not Critical to Spread In Vivo.

Authors:  Melanie Laura Duncan; Jacquelyn Horsington; Preethi Eldi; Zahrah Al Rumaih; Gunasegaran Karupiah; Timothy P Newsome
Journal:  Viruses       Date:  2018-03-05       Impact factor: 5.048

7.  Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).

Authors:  Eric M Mucker; Arthur J Goff; Joshua D Shamblin; Douglas W Grosenbach; Inger K Damon; Jason M Mehal; Robert C Holman; Darin Carroll; Nadia Gallardo; Victoria A Olson; Cody J Clemmons; Paul Hudson; Dennis E Hruby
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.938

8.  Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus.

Authors:  Anuja Mathew; Joel O'Bryan; William Marshall; Girish J Kotwal; Masanori Terajima; Sharone Green; Alan L Rothman; Francis A Ennis
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.